Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: J Invest Dermatol. 2020 May 25;141(1):182–184.e1. doi: 10.1016/j.jid.2020.04.027

Figure 2. JAKi reverse depigmentation in vitiligo but do not clear Trm in the skin.

Figure 2.

(a) Reversal experiments were completed according to the schedule above. (b) Photographs of mouse tails at the beginning and end of treatment after 8 weeks. (c) Change in tail pigment was calculated using before and after photos of each mouse. PMEL count within the epidermis (d) and dermis (e) was assessed at the end of treatment (each dot represents one animal; n=13 vehicle, 14 tofacitinib, and 8 ruxolitinib). (f) Resident memory T cells (Trm) were stained in the epidermis and quantified after treatment (n=6 vehicle, 8 tofacitinib, and 8 ruxolitinib pooled from 2 separate experiments).